Celltrion won the patent suit and accelerated global commercialization over its breast cancer treatment
As Celltrion won the formulation patent suit over the original product of the breast cancer biosimilar ‘Herzuma,’ the company is now able to actively take procedures for its domestic sales and global commercialization.
According to Celltrion on the 21st, the Intellectual Property Tribunal ruled ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
